The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Open accessAbstract
Immune checkpoint inhibitors (ICIs) produce durable responses in some melanoma patients, but many patients derive no clinical benefit, and the molecular underpinnings of such resistance remain elusive. Here, we leveraged single-cell RNA sequencing (scRNA-seq) from 33 melanoma tumors and computational analyses to interrogate malignant cell states that promote immune evasion. We identified a resistance program expressed by malignant cells that is associated with T cell exclusion and immune evasion. The program is expressed prior to immunotherapy, characterizes cold niches in situ, and predicts clinical responses to anti-PD-1 therapy in an independent cohort of 112 melanoma patients. CDK4/6-inhibition represses this program in individual malignant cells, induces senescence, and reduces melanoma tumor outgrowth in mouse models in vivo when given in combination with immunotherapy. Our study provides a high-resolution landscape of ICI-resistant cell states, identifies clinically predictive signatures, and suggests new therapeutic strategies to overcome immunotherapy resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinically relevant mechanisms of include mutations in beta-2-microglobulin (B2M) resulting in loss of MHC Class I presentation, downregulation of the antigen presentation machinery, and mutations in the IFNγ-JAK/STAT pathway that impair response to T cell mediated anti-tumor activity7–9.”
From Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion (2021) · cites this paper as [9]
In the citing paper
“perturbations of B2M, HLA-A, JAK1, JAK2, STAT1, IFNGR1 and IFNGR2 (Fig. 2d,e, Extended Data Fig. 3e,f, Supplementary Table 2) conferred immune evasion, consistent with clinical mechanisms of resistance to immunotherapy7–9.”
From Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion (2021) · cites this paper as [9]
In the citing paper
“We previously identified an ICR signature, which is predictive of intrinsic resistance to ICI, in a subset of malignant cells in patients with metastatic melanoma using scRNA-seq9.”
From Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion (2021) · cites this paper as [9]
In the citing paper
“consistent with our previously reported patient and pre-clinical data, where we demonstrate that upregulation of MYC and CDK4/6 (and their transcriptional targets) was associated with increased resistance to immunotherapy, and CDK4/6 inhibitors reduced resistance in human and pre-clinical melanoma models9.”
From Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion (2021) · cites this paper as [9]
In the citing paper
“This occurs either upon the derepression of endogenous retroviruses and consequent nucleic acid sensing (Goel et al., 2017; Vanpouille-Box et al., 2019) or following the establishment of a permanent cell cycle blockage (i.e., cellular senescence) characterized by an abundant secretory component, the so-called senescence-associated secretory phenotype (SASP) (Jerby-Arnon et al., 2018).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Jerby-Arnon et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
(2008) · Journal of Machine Learning Research · Cited by 33,051
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Robust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 999
Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility
Leonard‐Murali, S., Bhaskarla, C., Yadav, G. S., Maurya, S. K., Galiveti, C. R., Tobin, J. A., Kann, R. J., Ashwat, E., Murphy, P. S., Chakka, A. B., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46906-4 · Cited by 45
The immunosuppressive landscape in tumor microenvironment
Liu, W., Zhou, H., Lai, W., Hu, C., Xu, R., Gu, P., Luo, M., Zhang, R., & Li, G. (2024) · Immunologic Research · doi:10.1007/s12026-024-09483-8 · Cited by 44
Large-scale pharmacogenomic studies and drug response prediction for personalized cancer medicine
Feng, F., Shen, B., Mou, X., Li, Y., & Li, H. (2021) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2021.03.007 · Cited by 43
Subeh, Z. Y. A., Poschel, D. B., Redd, P. S., Klement, J. D., Merting, A. D., Yang, D., Mehta, M., Shi, H., Colson, Y. L., Oberlies, N. H., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c04420 · Cited by 41
Computational approaches for characterizing the tumor immune microenvironment
Liu, C. C., Steen, C. B., & Newman, A. M. (2019) · Immunology · doi:10.1111/imm.13101 · Cited by 41
A Bis-Indole–Derived NR4A1 Antagonist Induces PD-L1 Degradation and Enhances Antitumor Immunity
Karki, K., Wright, G. A., Mohankumar, K., Jin, U.-H., Zhang, X.-H., & Safe, S. H. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2314 · Cited by 40
Zhao, Q., Molina‐Portela, M. D. P., Parveen, A. A., Adler, A. P., Adler, C., Hock, E., Wang, W., Ni, M., Wei, Y., Atwal, G. S., et al. (2020) · Angiogenesis · doi:10.1007/s10456-020-09727-9 · Cited by 41
Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer
Zhang, F., Bai, H., Gao, R., Fei, K., Duan, J., Zhang, Z., Wang, J., & Hu, X. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02642-4 · Cited by 41
The tumour immune landscape and its implications in cutaneous melanoma
Attrill, G. H., Ferguson, P. M., Palendira, U., Long, G. V., Wilmott, J. S., & Scolyer, R. A. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12926 · Cited by 40
Karin, N. (2021) · Cancers · doi:10.3390/cancers13246317 · Cited by 41
Therapy sculpts the complex interplay between cancer and the immune system during tumour evolution
Thol, K., Pawlik, P., & McGranahan, N. (2022) · Genome Medicine · doi:10.1186/s13073-022-01138-3 · Cited by 47
Delorey, T. M., Ziegler, C. G. K., Heimberg, G., Normand, R., Yang, Y., Segerstolpe, Å., Abbondanza, D., Fleming, S. J., Subramanian, A., Montoro, D. T., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.25.430130 · Cited by 41
Self-citationEvolution and modulation of antigen-specific T cell responses in melanoma patients
Huuhtanen, J., Chen, L., Jokinen, E., Kasanen, H. H. E., Lönnberg, T., Kreutzman, A. S., Peltola, K. J., Hernberg, M., Wang, C., Yee, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33720-z · Cited by 38
Ibáñez‐Molero, S., Vliet, A. V., Poźniak, J., Hummelink, K., Terry, A. M., Monkhorst, K., Sanders, J., Hofland, I., Landeloos, E., Herck, Y. V., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2139074 · Cited by 42
Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation?
Yiong, C. S., Lin, T. P., Lim, V., Toh, T. B., & Yang, V. S. (2023) · Biomarker Research · doi:10.1186/s40364-023-00513-5 · Cited by 42
Wong, C. W., Evangelou, C., Sefton, K. N., Leshem, R., Zhang, W., Gopalan, V., Chattrakarn, S., Carro, M. L. F., Uzuner, E., Mole, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41737-1 · Cited by 42
Ren, F., Wang, L., Wang, Y., Wang, J., Wang, Y., Song, X., Zhang, G., Nie, F., & Lin, S. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06960-8 · Cited by 46
Self-citationYan, C. W., Saleh, N., Yang, J., Nebhan, C. A., Vilgelm, A. E., Reddy, E. P., Roland, J. T., Johnson, D. B., Chen, S., Shattuck-Brandt, R. L., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01366-y · Cited by 39
Shen, Y., Eng, J. S., Fajardo, F., Liang, L., Li, C., Collins, P. J., Tedesco, D., & Nolan-Stevaux, O. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004348 · Cited by 39
Feng, Z., Wang, T., Su, X., & Guo, S. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.665222 · Cited by 38
Gambi, G., Mengus, G., Davidson, G., Demesmaeker, E., Cuomo, A., Bonaldi, T., Katopodi, V., Malouf, G. G., Leucci, E., & Davidson, I. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0959 · Cited by 40
Lipid droplets are a metabolic vulnerability in melanoma
Lumaquin, D., Montal, E. D., Johns, E., Baggiolini, A., Huang, T. H., Ma, Y., LaPlante, C., Suresh, S., Studer, L., & White, R. M. (2023) · Nature Communications · doi:10.1038/s41467-023-38831-9 · Cited by 46
Xu, S., Chen, X., Ying, H., Chen, J., Ye, M., Lin, Z., Zhang, X., Shen, T., Li, Z., Zheng, Y., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12911-5 · Cited by 38
Knudsen, E. S., Shapiro, G. I., & Keyomarsi, K. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_281085 · Cited by 36
Freeman, S. S., Sade-Feldman, M., Kim, J., Stewart, C., Gonye, A. L. K., Ravi, A., Arniella, M. B., Gushterova, I., LaSalle, T. J., Blaum, E. M., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100500 · Cited by 41
Self-citationAhmadi, S., Sukprasert, P., Vegesna, R., Sinha, S., Schischlik, F., Artzi, N., Khuller, S., Schäffer, A. A., & Ruppin, E. (2022) · Nature Communications · doi:10.1038/s41467-022-29154-2 · Cited by 37
Kleeman, S. O., Thakir, T. M., Demestichas, B., Mourikis, N., Loiero, D., Ferrer, M., Bankier, S., Riazat-Kesh, Y. J. R. A., Lee, H., Chantzichristos, D., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100347 · Cited by 37
Roh, W., Geffen, Y., Cha, H., Miller, M. L., Anand, S. K., Kim, J., Heiman, D. I., Gainor, J. F., Laird, P. W., Cherniack, A. D., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0432 · Cited by 37
Kim, I., Diamond, M. S., Yuan, S., Kemp, S. B., Kahn, B., Li, Q., Lin, J. H., Li, J., Norgard, R. J., Thomas, S. K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46048-7 · Cited by 38
Self-citationGetting under the skin: The role of CDK4/6 in melanomas
Guo, L., Qi, J., Wang, H., Jiang, X. L., & Liu, Y. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112531 · Cited by 37
Discovery through clinical sequencing in oncology
Donoghue, M. T. A., Schram, A. M., Hyman, D. M., & Taylor, B. S. (2020) · Nature Cancer · doi:10.1038/s43018-020-0100-0 · Cited by 38
Allele-specific expression: applications in cancer and technical considerations
Robles‐Espinoza, C. D., Mohammadi, P., Bonilla, X., & Gutiérrez‐Arcelus, M. (2020) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2020.10.007 · Cited by 40
scLM: Automatic Detection of Consensus Gene Clusters Across Multiple Single-Cell Datasets
Song, Q., Su, J., Miller, L. D., & Zhang, W. (2020) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2020.09.002 · Cited by 37
Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges
Indini, A., Massi, D., Pirro, M., Roila, F., Grossi, F., Sahebkar, A., Glodde, N., Bald, T., & Mandalà, M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.06.005 · Cited by 38
B cells sustain inflammation and predict response to immune checkpoint blockade in human melanomaPreprint
Griss, J., Bauer, W. M., Wagner, C., Maurer‐Granofszky, M., Simon, M., Chen, M., Steinberger, P., Grabmeier‐Pfistershammer, K., Roka, F., Penz, T., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/478735 · Cited by 37
Self-citationZhang, Q., Jin, S., & Zou, X. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac1109 · Cited by 38
Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
Sahu, A. D., Wang, X., Munson, P. B., Klomp, J. P. G., Wang, X., Gu, S. S., Qian, G., Nicol, P., Zeng, Z., Wang, C., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0244 · Cited by 35
Self-citationChen, F., Yang, J., Guo, Y., Su, D., Sheng, Y., & Wu, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1140995 · Cited by 38
The transcriptional landscape of glycosylation-related genes in cancer
Rodríguez, E., Lindijer, D., van Vliet, S. J., García-Vallejo, J. J., & van Kooyk, Y. (2024) · iScience · doi:10.1016/j.isci.2024.109037 · Cited by 36
Single-Cell Deconvolution of Head and Neck Squamous Cell Carcinoma
Qi, Z., Liu, Y., Mints, M., Mullins, R. D. Z., Sample, R. A., Law, T. E., Barrett, T. F., Mazul, A. L., Jackson, R. S., Kang, S. Y., et al. (2021) · Cancers · doi:10.3390/cancers13061230 · Cited by 37
Self-citationT cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction
Pinkert, J., Boehm, H.-H., Trautwein, M., Doecke, W.-D., Wessel, F., Ge, Y., Gutierrez, E. M., Carretero, R., Freiberg, C., Gritzan, U., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.2008110 · Cited by 46
An integrative pan‐cancer analysis of the molecular and biological features of glycosyltransferases
Li, Y., Lin, Y., Aye, L., Dong, L., Zhang, C., Chen, F., Liu, Y., Fan, J., Gao, Q., Lu, H., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.872 · Cited by 35
Single-Cell Analysis in Immuno-Oncology
Christodoulou, M., & Zaravinos, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098422 · Cited by 35
Trani, C. A. D., Cirella, A., Arrizabalaga, L., Álvarez, M., Bella, Á., Fernández-Sendin, M., Russo-Cabrera, J. S., Gomar, C., Ardaiz, N., Teijeira, Á., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.07.020 · Cited by 35
Engineered biological nanoparticles as nanotherapeutics for tumor immunomodulation
Rahmat, J. N., Liu, J., Chen, T., Li, Z., & Zhang, Y. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00602f · Cited by 38
Screening for new macrophage therapeutics
Rodell, C. B., Koch, P. D., & Weissleder, R. (2019) · Theranostics · doi:10.7150/thno.34421 · Cited by 35
Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma
Galvani, E., Mundra, P. A., Valpione, S., García-Martínez, P. L., Smith, M., Greenall, J., Thakur, R., Helmink, B. A., Andrews, M. C., Boon, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14632-2 · Cited by 36
Advances in theranostic biomarkers for tumor immunotherapy
Bellesœur, A., Torossian, N., Amigorena, S., & Romano, E. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.02.005 · Cited by 34
Quantitative Single-Cell Proteomics as a Tool to Characterize Cellular HierarchiesPreprint
Schoof, E. M., Furtwängler, B., Üresin, N., Rapin, N., Savickas, S., Gentil, C., Lechman, E. R., Keller, U. A. D., Dick, J. E., & Porse, B. T. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/745679 · Cited by 41
Chen, C.-Y., Ueha, S., Ishiwata, Y., Shichino, S., Yokochi, S., Yang, D., Oppenheim, J. J., Ogiwara, H., Deshimaru, S., Kanno, Y., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0265 · Cited by 34
SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects
Rosenbaum, S. R., Tiago, M., Caksa, S., Capparelli, C., Purwin, T. J., Kumar, G., Glasheen, M. Q., Pomante, D., Kotas, D., Chervoneva, I., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110085 · Cited by 41
Pirozyan, M. R., McGuire, H. M., Emran, A. A., Tseng, H.-Y., Tiffen, J. C., Lee, J. H., Carlino, M. S., Menzies, A. M., Long, G. V., Scolyer, R. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00372 · Cited by 34
T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction
Pinkert, J., Boehm, H.-H., Trautwein, M., Doecke, W., Wessel, F., Ge, Y., Gutierrez, E. M., Carretero, R., Freiberg, C., Gritzan, U., et al. (2022) · University of Regensburg Publication Server (University of Regensburg) · Cited by 34
Immunomodulatory effects of CDK4/6 inhibitors
Zhang, S., Xu, Q., Sun, W., Zhou, J., & Zhou, J. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188912 · Cited by 34
Pich-Bavastro, C., Yerly, L., Domizio, J. D., Tissot-Renaud, S., Gilliet, M. F., & Kuonen, F. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0219 · Cited by 35
An iron-rich subset of macrophages promotes tumor growth through a Bach1-Ednrb axis
Folkert, I. W., Arocho, W. A. M., To, T. K. J., Devalaraja, S., Molina, I. S., Shoush, J., Mohei, H., Zhai, L., Akhtar, M. N., Kochat, V., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20230420 · Cited by 35
Ghisoni, E., Benedetti, F., Minasyan, A., Desbuisson, M., Cunnea, P., Grimm, A. J., Fahr, N., Capt, C., Rayroux, N., Carlo, F. D., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.07.005 · Cited by 37
Basu, R., Kulkarni, P., Qian, Y., Walsh, C., Arora, P., Davis, E., Duran‐Ortiz, S., Funk, K. R., Ibarra, D., Kruse, C. P. S., et al. (2019) · Cancers · doi:10.3390/cancers11091352 · Cited by 34
Insights into Fibroblast Plasticity
Tsang, M., Quesnel, K., Vincent, K. M., Hutchenreuther, J., Postovit, L.-M. M., & Leask, A. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2019.09.006 · Cited by 34
Gokuldass, A., Draghi, A., Papp, K., Borch, T. H., Nielsen, M., Westergaard, M. C. W., Andersen, R. S., Schina, A., Bol, K. F., Chamberlain, C. A., et al. (2020) · Cancers · doi:10.3390/cancers12113344 · Cited by 34
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
Hu‐Lieskovan, S., Bhaumik, S., Dhodapkar, K. M., Grivel, J., Gupta, S. V., Hanks, B. A., Janetzki, S., Kleen, T. O., Koguchi, Y., Lund, A. W., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000705 · Cited by 35
Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?
Lelliott, E. J., Sheppard, K. E., & McArthur, G. A. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00273-9 · Cited by 34
Li, J., & Stanger, B. Z. (2019) · Science · doi:10.1126/science.aau9861 · Cited by 34
Wang, J., Li, L., & Xu, Z. P. (2023) · Small Methods · doi:10.1002/smtd.202301005 · Cited by 34
Tumor endothelial cell autophagy is a key vascular‐immune checkpoint in melanoma
Verhoeven, J., Jacobs, K., Rizzollo, F., Lodi, F., Hua, Y., Poźniak, J., Srinivasan, A. N., Houbaert, D., Shankar, G., More, S., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202318028 · Cited by 35
Cellular senescence offers distinct immunological vulnerabilities in cancer
Zhou, L., Ma, B., & Ruscetti, M. A. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.11.010 · Cited by 40
Single-Cell Sequencing: Genomic and Transcriptomic Approaches in Cancer Cell Biology
Ortega-Batista, A., Jaén-Alvarado, Y., Moreno-Labrador, D., Gómez, N., García, G., & Guerrero, E. N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052074 · Cited by 37
ERK1/2 signaling regulates the immune microenvironment and macrophage recruitment in glioblastoma
Lailler, C., Louandre, C., Morisse, M. C., Lhossein, T., Godin, C., Lottin, M., Constans, J., Chauffert, B., Galmiche, A., & Saidak, Z. (2019) · Bioscience Reports · doi:10.1042/bsr20191433 · Cited by 33
Seumois, G., & Vijayanand, P. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.09.014 · Cited by 30
Bilateral murine tumor models for characterizing the response to immune checkpoint blockade
Zemek, R. M., Fear, V. S., Forbes, C., de Jong, E., Casey, T. H., Boon, L., Lassmann, T., Bosco, A., Millward, M., Nowak, A. K., et al. (2020) · Nature Protocols · doi:10.1038/s41596-020-0299-3 · Cited by 31
The future of targeted kinase inhibitors in melanoma
Caksa, S., Baqai, U., & Aplin, A. E. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108200 · Cited by 37
Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity
Melms, J. C., Vallabhaneni, S., Mills, C. E., Yapp, C., Chen, J.-Y., Morelli, E., Waszyk, P., Kumar, S., Deming, D., Moret, N., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-2330 · Cited by 33
Self-citationSaleh, R., Nair, V. S., Toor, S. M., Taha, R. Z., Murshed, K., Al‐Dhaheri, M., Khawar, M., Petkar, M. A., Nada, M. A., Al‐Ejeh, F., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001294 · Cited by 34
Targeting DNA Repair, Cell Cycle, and Tumor Microenvironment in B Cell Lymphoma
Bröckelmann, P. J., de Jong, M. R. W., & Jachimowicz, R. D. (2020) · Cells · doi:10.3390/cells9102287 · Cited by 31
The RUNX1/RUNX1T1 network: translating insights into therapeutic options
Swart, L. E., & Heidenreich, O. T. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.11.005 · Cited by 32
Applications of Single-Cell Omics to Dissect Tumor Microenvironment
Guo, T., Li, W., & Cai, X. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.548719 · Cited by 33
Jawa, Y., Yadav, P., Gupta, S., Mathan, S. V., Pandey, J., Saxena, A. K., Kateriya, S., Tiku, A. B., Mondal, N., Bhattacharya, J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.676948 · Cited by 36
Foroutan, M., Molania, R., Pfefferle, A., Behrenbruch, C., Scheer, S., Kallies, A., Speed, T. P., Cursons, J., & Huntington, N. D. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0137 · Cited by 35
The Role of Oncogenes and Redox Signaling in the Regulation of PD-L1 in Cancer
Glorieux, C., Xia, X., & Huang, P. (2021) · Cancers · doi:10.3390/cancers13174426 · Cited by 33
Paschen, A., Melero, I., & Ribas, A. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070220-111016 · Cited by 32
Combination Approaches to Target PD-1 Signaling in Cancer
Moore, E. K., Strazza, M., & Mor, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.927265 · Cited by 32
Albrecht, L. J., Hoewner, A., Griewank, K., Lueong, S., Neuhoff, N. V., Horn, P., Sucker, A., Paschen, A., Livingstone, E., Ugurel, S., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1090 · Cited by 31
Self-citationSu, S., You, S., Wang, Y., Tamukong, P. K., Quist, M. J., Grasso, C. S., & Kim, H. L. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.216034 · Cited by 31
Sctensor detects many-to-many cell–cell interactions from single cell RNA-sequencing data
Tsuyuzaki, K., Ishii, M., & Nikaido, I. (2023) · BMC Bioinformatics · doi:10.1186/s12859-023-05490-y · Cited by 77
Single-Cell RNA Sequencing for Studying Human Cancers
Aran, D. (2023) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-020722-091857 · Cited by 31
Targeting the Molecular and Immunologic Features of Leiomyosarcoma
Cope, B. M., Traweek, R. S., Lazcano, R., Keung, E. Z.-Y., Lazar, A. J., Roland, C. L., & Nassif, E. F. (2023) · Cancers · doi:10.3390/cancers15072099 · Cited by 33
Yang, L., Hu, Q., & Huang, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137208 · Cited by 32
Hu, M., & Chikina, M. D. (2024) · Genome biology · doi:10.1186/s13059-024-03292-w · Cited by 31
Revisiting T-cell adhesion molecules as potential targets for cancer immunotherapy: CD226 and CD2
Jo, Y., Sim, H.-I., Yun, B., Park, Y., & Jin, H. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01317-9 · Cited by 31
Poźniak, J., Roda, N., Landeloos, E., Antoranz, A., Herck, Y. V., Visscher, A. D., Demaerel, P. G., Vanwynsberghe, L., Declercq, J., Gkemisis, C., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1208 · Cited by 33
Non-invasive profiling of the tumour microenvironment with spatial ecotypes
Zhang, W., Brown, E. L., Usmani, A., Earland, N. J., Kang, M., Olelewe, C., Viswanathan, A., Chauhan, P. S., Steen, C. B., Jeon, H. S., et al. (2026) · Nature · doi:10.1038/s41586-026-10452-4 · Cited by 35
Kinalis, S., Nielsen, F. C., Winther, O., & Bagger, F. O. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2952-9 · Cited by 29
Mitchell, K. G., Amini, B., Wang, Y., Carter, B. W., Godoy, M. C. B., Parra, E. R., Behrens, C., Villalobos, P. A., Reuben, A., Lee, J. J., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02560-5 · Cited by 32
Self-citationCharge and Size Dual Switchable Nanocage for Novel Triple‐Interlocked Combination Therapy Pattern
Yang, R., Zhang, Z., Fu, S., Hou, T., Mu, W., Liang, S., Gao, T., Guan, L., Fang, Y., Liu, Y., et al. (2020) · Advanced Science · doi:10.1002/advs.202000906 · Cited by 31
Sun, S., Xu, L., Zhang, X., Pang, L., Long, Z., Deng, C., Zhu, J., Zhou, S., Wan, L., Pang, B., et al. (2021) · Cancers · doi:10.3390/cancers13071639 · Cited by 32
Zhang, Z., Luo, L., Xing, C., Chen, Y., Xu, P., Mao, L., Zeng, L., Li, C., Ghosh, S., Manna, D. D., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00263-z · Cited by 31
Yang, Q., Ma, X., Xiao, Y., Zhang, T., Yang, L., Yang, S., Liang, M., Wang, S., Wu, Z., Xu, Z., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.024 · Cited by 31
Self-citationDinavahi, S. S., Chen, Y., Punnath, K., Berg, A. S., Herlyn, M., Foroutan, M., Huntington, N. D., & Robertson, G. P. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0587 · Cited by 31
Self-citationMelo, L. M. N., Herrera-Rios, D., Hinze, D., Löffek, S., Ozel, I., Turiello, R., Klein, J., Leonardelli, S., Westedt, I. V., Al-Matary, Y. S., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004150 · Cited by 34
Self-citationJagadeesh, K. A., Dey, K. K., Montoro, D. T., Mohan, R. R., Gazal, S., Engreitz, J., Xavier, R. J., Price, A. L., & Regev, A. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.19.436212 · Cited by 31
Self-citation
Metadata
- Authors
- Jerby-Arnon, L., Shah, P., Cuoco, M. S., Rodman, C., Su, M.-J., Melms, J. C., Leeson, R., Kanodia, A., Mei, S., Lin, J.-R., Wang, S., Rabasha, B., Liu, D., Zhang, G., Margolais, C., Ashenberg, O., Ott, P. A., Buchbinder, E. I., Haq, R., Hodi, F. S., Boland, G. M., Sullivan, R. J., Frederick, D. T., Miao, B., Moll, T., Flaherty, K. T., Herlyn, M., Jenkins, R. W., Thummalapalli, R., Kowalczyk, M. S., Cañadas, I., Schilling, B., Cartwright, A. N. R., Luoma, A. M., Malu, S., Hwu, P., Bernatchez, C., Forget, M.-A., Barbie, D. A., Shalek, A. K., Tirosh, I., Sorger, P. K., Wucherpfennig, K., Van Allen, E. M., Schadendorf, D., Johnson, B. E., Rotem, A., Rozenblatt-Rosen, O., Garraway, L. A., Yoon, C. H., Izar, B., & Regev, A.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Broad Institute (US)
- Harvard University (US)
- The Wistar Institute (US)
- Massachusetts General Hospital (US)
- Essen University Hospital (DE)
- The University of Texas MD Anderson Cancer Center (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Izar, Benjamin
- ORCID
- Shah, Parin
- Cuoco, Michael S.
- Rodman, Christopher
- Melms, Johannes C.
- Kanodia, Abhay
- Mei, Shaolin
- Lin, Jia-Ren
- Wang, Shu
- Liu, David
- Zhang, Gao
- Ashenberg, Orr
- Ott, Patrick A.
- Buchbinder, Elizabeth I.
- Haq, Rizwan
- Hodi, F. Stephen
- Boland, Genevieve M.
- Sullivan, Ryan J.
- Frederick, Dennie T.
- Moll, Tabea
- Flaherty, Keith T.
- Herlyn, Meenhard
- Jenkins, Russell W.
- Thummalapalli, Rohit
- Kowalczyk, Monika S.
- Cañadas, Israel
- Schilling, Bastian
- Cartwright, Adam N.R.
- Luoma, Adrienne M.
- Hwu, Patrick
- Bernatchez, Chantale
- Forget, Marie-Andrée
- Barbie, David A.
- Shalek, Alex K.
- Tirosh, Itay
- Sorger, Peter K.
- Wucherpfennig, Kai
- Schadendorf, Dirk
- Johnson, Bruce E.
- Rotem, Asaf
- Garraway, Levi A.
- Yoon, Charles H.
- Izar, Benjamin
- Regev, Aviv
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 175
- Issue
- 4
- Pages
- 984-997.e24
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC6410377
- OpenAlex
- W2898830231
- Cited by
- 1,429
- References
- 47
- Citations by year
- 2026: 166 · 2025: 187 · 2024: 195 · 2023: 207 · 2022: 203 · 2021: 202 · 2020: 161 · 2019: 102 · 2018: 3
- FWCI
- 44.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-nd)
- Funders
- CRI
- NCI (K08-CA222663, 1U24CA180922, R33-CA202820)
- DFCI
- SITC
- Klarman Cell Observatory
- STARR Cancer Consortium
- Koch Institute (P30-CA14051)
- Harvard
- MIT
- AMRF
- Broad Institute
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- melanoma, immune checkpoint inhibitors, immunotherapy resistance, T-cell exclusion, immune evasion, cold tumors, anti-PD-1 therapy, CDK4/6 inhibition, cellular senescence, cancer cell states, predictive biomarkers, combination therapy
- MeSH terms
- Aged, Aged, 80 and over, Animals, Antineoplastic Agents, Female, Humans, Immunotherapy, Male, Melanoma, Mice, Inbred C57BL, Middle Aged, T-Lymphocytes, Tumor Escape, Cell Line, Tumor, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
